Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

Mary Ellen Taplin, Meredith M. Regan, Yoo Joung Ko, Glenn J. Bubley, Stephen E. Duggan, Lillian Werner, Tomasz M. Beer, Christopher W. Ryan, Paul Mathew, Shi Ming Tu, Samuel R Denmeade, William K. Oh, Oliver Sartor, Christos S. Mantzoros, Roger Rittmaster, Philip W. Kantoff, Steven P. Balk

Research output: Contribution to journalArticle

Abstract

Purpose: Increasing evidence indicates that enhanced intratumoral androgen synthesis contributes to prostate cancer progression after androgen deprivation therapy. This phase II study was designed to assess responses to blocking multiple steps in androgen synthesis with inhibitors of CYP17A1 (ketoconazole) and type I and II 5α-reductases (dutasteride) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: Fifty-seven men with CRPC were continued on gonadal suppression and treated with ketoconazole (400 mg thrice daily), hydrocortisone (30 mg/AM, 10 mg/PM), and dutasteride (0.5 mg/d). Results: Prostate-specific antigen response rate (≥50% decline) was 56% (32 of 57; 95% confidence interval, 42.4-69.3%); the median duration of response was 20 months. In patients with measurable disease, 6 of 20 (30%) responded by the Response Evaluation Criteria in Solid Tumors. Median duration of treatment was 8 months; 9 patients remained on therapy with treatment durations censored at 18 to 32 months. Median time to progression was 14.5 months. Grade 3 toxicities occurred in 32% with only one reported grade 4 (thrombosis) toxicity. Dehydroepiandrosterone sulfate declined by 89%, androstenedione by 56%, and testosterone by 66%, and dihydrotestosterone declined to below detectable levels compared with baseline levels with testicular suppression alone. Median baseline levels and declines in dehydroepiandrosterone sulfate, androstenedione, testosterone, and dihydrotestosterone were not statistically different in the responders versus nonresponders, and hormone levels were not significantly increased from nadir levels at relapse. Conclusion: The response proportion to ketoconazole, hydrocortisone, and dutasteride was at least comparable with previous studies of ketoconazole alone, whereas time to progression was substantially longer. Combination therapies targeting multiple steps in androgen synthesis warrant further investigation.

Original languageEnglish (US)
Pages (from-to)7099-7105
Number of pages7
JournalClinical Cancer Research
Volume15
Issue number22
DOIs
StatePublished - Nov 15 2009

Fingerprint

Ketoconazole
Castration
Androgens
Hydrocortisone
Prostatic Neoplasms
Dehydroepiandrosterone Sulfate
Androstenedione
Dihydrotestosterone
Testosterone
Therapeutics
Prostate-Specific Antigen
Oxidoreductases
Thrombosis
Research Design
Dutasteride
Hormones
Confidence Intervals
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. / Taplin, Mary Ellen; Regan, Meredith M.; Ko, Yoo Joung; Bubley, Glenn J.; Duggan, Stephen E.; Werner, Lillian; Beer, Tomasz M.; Ryan, Christopher W.; Mathew, Paul; Tu, Shi Ming; Denmeade, Samuel R; Oh, William K.; Sartor, Oliver; Mantzoros, Christos S.; Rittmaster, Roger; Kantoff, Philip W.; Balk, Steven P.

In: Clinical Cancer Research, Vol. 15, No. 22, 15.11.2009, p. 7099-7105.

Research output: Contribution to journalArticle

Taplin, ME, Regan, MM, Ko, YJ, Bubley, GJ, Duggan, SE, Werner, L, Beer, TM, Ryan, CW, Mathew, P, Tu, SM, Denmeade, SR, Oh, WK, Sartor, O, Mantzoros, CS, Rittmaster, R, Kantoff, PW & Balk, SP 2009, 'Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer', Clinical Cancer Research, vol. 15, no. 22, pp. 7099-7105. https://doi.org/10.1158/1078-0432.CCR-09-1722
Taplin, Mary Ellen ; Regan, Meredith M. ; Ko, Yoo Joung ; Bubley, Glenn J. ; Duggan, Stephen E. ; Werner, Lillian ; Beer, Tomasz M. ; Ryan, Christopher W. ; Mathew, Paul ; Tu, Shi Ming ; Denmeade, Samuel R ; Oh, William K. ; Sartor, Oliver ; Mantzoros, Christos S. ; Rittmaster, Roger ; Kantoff, Philip W. ; Balk, Steven P. / Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 22. pp. 7099-7105.
@article{a28ed541e2ea41e3b1c31758cbb97fa8,
title = "Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer",
abstract = "Purpose: Increasing evidence indicates that enhanced intratumoral androgen synthesis contributes to prostate cancer progression after androgen deprivation therapy. This phase II study was designed to assess responses to blocking multiple steps in androgen synthesis with inhibitors of CYP17A1 (ketoconazole) and type I and II 5α-reductases (dutasteride) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: Fifty-seven men with CRPC were continued on gonadal suppression and treated with ketoconazole (400 mg thrice daily), hydrocortisone (30 mg/AM, 10 mg/PM), and dutasteride (0.5 mg/d). Results: Prostate-specific antigen response rate (≥50{\%} decline) was 56{\%} (32 of 57; 95{\%} confidence interval, 42.4-69.3{\%}); the median duration of response was 20 months. In patients with measurable disease, 6 of 20 (30{\%}) responded by the Response Evaluation Criteria in Solid Tumors. Median duration of treatment was 8 months; 9 patients remained on therapy with treatment durations censored at 18 to 32 months. Median time to progression was 14.5 months. Grade 3 toxicities occurred in 32{\%} with only one reported grade 4 (thrombosis) toxicity. Dehydroepiandrosterone sulfate declined by 89{\%}, androstenedione by 56{\%}, and testosterone by 66{\%}, and dihydrotestosterone declined to below detectable levels compared with baseline levels with testicular suppression alone. Median baseline levels and declines in dehydroepiandrosterone sulfate, androstenedione, testosterone, and dihydrotestosterone were not statistically different in the responders versus nonresponders, and hormone levels were not significantly increased from nadir levels at relapse. Conclusion: The response proportion to ketoconazole, hydrocortisone, and dutasteride was at least comparable with previous studies of ketoconazole alone, whereas time to progression was substantially longer. Combination therapies targeting multiple steps in androgen synthesis warrant further investigation.",
author = "Taplin, {Mary Ellen} and Regan, {Meredith M.} and Ko, {Yoo Joung} and Bubley, {Glenn J.} and Duggan, {Stephen E.} and Lillian Werner and Beer, {Tomasz M.} and Ryan, {Christopher W.} and Paul Mathew and Tu, {Shi Ming} and Denmeade, {Samuel R} and Oh, {William K.} and Oliver Sartor and Mantzoros, {Christos S.} and Roger Rittmaster and Kantoff, {Philip W.} and Balk, {Steven P.}",
year = "2009",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-09-1722",
language = "English (US)",
volume = "15",
pages = "7099--7105",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

AU - Taplin, Mary Ellen

AU - Regan, Meredith M.

AU - Ko, Yoo Joung

AU - Bubley, Glenn J.

AU - Duggan, Stephen E.

AU - Werner, Lillian

AU - Beer, Tomasz M.

AU - Ryan, Christopher W.

AU - Mathew, Paul

AU - Tu, Shi Ming

AU - Denmeade, Samuel R

AU - Oh, William K.

AU - Sartor, Oliver

AU - Mantzoros, Christos S.

AU - Rittmaster, Roger

AU - Kantoff, Philip W.

AU - Balk, Steven P.

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Purpose: Increasing evidence indicates that enhanced intratumoral androgen synthesis contributes to prostate cancer progression after androgen deprivation therapy. This phase II study was designed to assess responses to blocking multiple steps in androgen synthesis with inhibitors of CYP17A1 (ketoconazole) and type I and II 5α-reductases (dutasteride) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: Fifty-seven men with CRPC were continued on gonadal suppression and treated with ketoconazole (400 mg thrice daily), hydrocortisone (30 mg/AM, 10 mg/PM), and dutasteride (0.5 mg/d). Results: Prostate-specific antigen response rate (≥50% decline) was 56% (32 of 57; 95% confidence interval, 42.4-69.3%); the median duration of response was 20 months. In patients with measurable disease, 6 of 20 (30%) responded by the Response Evaluation Criteria in Solid Tumors. Median duration of treatment was 8 months; 9 patients remained on therapy with treatment durations censored at 18 to 32 months. Median time to progression was 14.5 months. Grade 3 toxicities occurred in 32% with only one reported grade 4 (thrombosis) toxicity. Dehydroepiandrosterone sulfate declined by 89%, androstenedione by 56%, and testosterone by 66%, and dihydrotestosterone declined to below detectable levels compared with baseline levels with testicular suppression alone. Median baseline levels and declines in dehydroepiandrosterone sulfate, androstenedione, testosterone, and dihydrotestosterone were not statistically different in the responders versus nonresponders, and hormone levels were not significantly increased from nadir levels at relapse. Conclusion: The response proportion to ketoconazole, hydrocortisone, and dutasteride was at least comparable with previous studies of ketoconazole alone, whereas time to progression was substantially longer. Combination therapies targeting multiple steps in androgen synthesis warrant further investigation.

AB - Purpose: Increasing evidence indicates that enhanced intratumoral androgen synthesis contributes to prostate cancer progression after androgen deprivation therapy. This phase II study was designed to assess responses to blocking multiple steps in androgen synthesis with inhibitors of CYP17A1 (ketoconazole) and type I and II 5α-reductases (dutasteride) in patients with castration-resistant prostate cancer (CRPC). Experimental Design: Fifty-seven men with CRPC were continued on gonadal suppression and treated with ketoconazole (400 mg thrice daily), hydrocortisone (30 mg/AM, 10 mg/PM), and dutasteride (0.5 mg/d). Results: Prostate-specific antigen response rate (≥50% decline) was 56% (32 of 57; 95% confidence interval, 42.4-69.3%); the median duration of response was 20 months. In patients with measurable disease, 6 of 20 (30%) responded by the Response Evaluation Criteria in Solid Tumors. Median duration of treatment was 8 months; 9 patients remained on therapy with treatment durations censored at 18 to 32 months. Median time to progression was 14.5 months. Grade 3 toxicities occurred in 32% with only one reported grade 4 (thrombosis) toxicity. Dehydroepiandrosterone sulfate declined by 89%, androstenedione by 56%, and testosterone by 66%, and dihydrotestosterone declined to below detectable levels compared with baseline levels with testicular suppression alone. Median baseline levels and declines in dehydroepiandrosterone sulfate, androstenedione, testosterone, and dihydrotestosterone were not statistically different in the responders versus nonresponders, and hormone levels were not significantly increased from nadir levels at relapse. Conclusion: The response proportion to ketoconazole, hydrocortisone, and dutasteride was at least comparable with previous studies of ketoconazole alone, whereas time to progression was substantially longer. Combination therapies targeting multiple steps in androgen synthesis warrant further investigation.

UR - http://www.scopus.com/inward/record.url?scp=72549108829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549108829&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1722

DO - 10.1158/1078-0432.CCR-09-1722

M3 - Article

C2 - 19887483

AN - SCOPUS:72549108829

VL - 15

SP - 7099

EP - 7105

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -